Suppr超能文献

CXCL14 优先与稳态趋化因子受体系统协同作用。

CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems.

机构信息

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.

出版信息

Front Immunol. 2020 Oct 5;11:561404. doi: 10.3389/fimmu.2020.561404. eCollection 2020.

Abstract

Reflecting their importance in immunity, the activity of chemokines is regulated on several levels, including tissue and context-specific expression and availability of their cognate receptor on target cells. Chemokine synergism, affecting both chemokine and chemokine receptor function, has emerged as an additional control mechanism. We previously demonstrated that CXCL14 is a positive allosteric modulator of CXCR4 in its ability to synergize with CXCL12 in diverse cellular responses. Here, we have extended our study to additional homeostatic, as well as a selection of inflammatory chemokine systems. We report that CXCL14 strongly synergizes with low (sub-active) concentrations of CXCL13 and CCL19/CCL21 in chemotaxis with immune cells expressing the corresponding receptors CXCR5 and CCR7, respectively. CXCL14 by itself was inactive, not only on cells expressing CXCR5 or CCR7 but also on cells expressing any other known conventional or atypical chemokine receptor, as assessed by chemotaxis and/or β-arrestin recruitment assays. Furthermore, synergistic migration responses between CXCL14 and inflammatory chemokines CXCL10/CXCL11 and CCL5, targeting CXCR3 and CCR5, respectively, were marginal and occasional synergistic Ca flux responses were observed. CXCL14 bound to 300-19 cells and interfered with CCL19 binding to CCR7-expressing cells, suggesting that these cellular interactions contributed to the reported CXCL14-mediated synergistic activities. We propose a model whereby tissue-expressed CXCL14 contributes to cell localization under steady-state conditions at sites with prominent expression of homeostatic chemokines.

摘要

反映其在免疫中的重要性,趋化因子的活性在多个水平上受到调节,包括组织和特定于上下文的表达以及靶细胞上其同源受体的可用性。趋化因子协同作用影响趋化因子和趋化因子受体的功能,已成为另一种控制机制。我们之前证明 CXCL14 是 CXCR4 的正变构调节剂,能够与其协同作用,在多种细胞反应中与 CXCL12 协同作用。在这里,我们将研究扩展到其他稳态以及选择炎症趋化因子系统。我们报告说,CXCL14 与低(亚活性)浓度的 CXCL13 和 CCL19/CCL21 强烈协同作用,在表达相应受体 CXCR5 和 CCR7 的免疫细胞的趋化作用中分别。CXCL14 本身是无活性的,不仅在表达 CXCR5 或 CCR7 的细胞上无活性,而且在表达任何其他已知常规或非典型趋化因子受体的细胞上也无活性,如通过趋化作用和/或β-arrestin 募集测定法评估的。此外,分别针对 CXCR3 和 CCR5 的趋化因子 CXCL10/CXCL11 和 CCL5 与 CXCL14 之间的协同迁移反应是微不足道的,并且偶尔会观察到协同 Ca 流反应。CXCL14 与 300-19 细胞结合并干扰 CCL19 与表达 CCR7 的细胞结合,这表明这些细胞相互作用促成了报道的 CXCL14 介导的协同活性。我们提出了一个模型,即在稳态条件下,组织表达的 CXCL14 有助于在家稳态趋化因子表达突出的部位中细胞定位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/7570948/1ced85523dfe/fimmu-11-561404-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验